JPMorgan Chase & Co. continued to hold its position in ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 200,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. JPMorgan Chase & Co. owned 0.31% of ContraVir Pharmaceuticals worth $116,000 at the end of the most recent quarter.
ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/10/31/jpmorgan-chase-co-maintains-position-in-contravir-pharmaceuticals-inc-ctrv.html.
ContraVir Pharmaceuticals Inc (CTRV) opened at 0.5198 on Tuesday. ContraVir Pharmaceuticals Inc has a 1-year low of $0.45 and a 1-year high of $2.37. The stock has a 50 day moving average price of $0.58 and a 200-day moving average price of $0.65. The stock’s market cap is $40.54 million.
Separately, Maxim Group set a $4.00 target price on ContraVir Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, October 19th.
ContraVir Pharmaceuticals Profile
ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100.
What are top analysts saying about ContraVir Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ContraVir Pharmaceuticals Inc and related companies.